Skip to main content
. 2020 Apr 30;2020:5691671. doi: 10.1155/2020/5691671

Figure 6.

Figure 6

RAB9A promotes the malignant behavior of liver cancer cells by activating the AKT/mTOR signaling pathway. AKT signaling pathway components were detected (a) and quantified (b) by western blot. (c) Cell proliferation of Hep3b cells was detected by CCK8 assay. (d) The invasion of Hep3b cells was determined by transwell assay. OV: overexpression of RAB9A; OV+BEZ235: overexpression of RAB9A+treatment of double-effect inhibitor (BEZ235) which inhibits AKT and mTOR phosphorylation. P < 0.05.